Middleway Nutrition
Evidence-based GLP-1 and peptide science.
Clear clinical research, dosing context, safety tradeoffs, and practical guides organized into two focused archives.
Latest Articles
20 articles
Rybelsus Guide: Oral Semaglutide for Type 2 Diabetes (2026)
Rybelsus is the only FDA-approved GLP-1 pill for type 2 diabetes — 3, 7, and 14 mg daily doses, strict empty-stomach rule, A1C drops of 1.0-1.5%, and a $1,027.51 monthly list price. Here is what the PIONEER trials, SNAC absorption, and real-world use actually show.
GLP-1Trulicity Guide: Weekly Dulaglutide for Type 2 Diabetes (2026)
Trulicity (dulaglutide) is Eli Lilly's once-weekly GLP-1 injection, approved in 2014 for type 2 diabetes. Doses run 0.75 to 4.5 mg, the REWIND trial showed a 12% MACE reduction, and the list price sits near $887 per month. Here is the full breakdown.
GLP-1Victoza Guide: Daily Liraglutide for Type 2 Diabetes (2026)
Victoza (liraglutide) is the original daily GLP-1 injection for type 2 diabetes — approved in 2010, doses of 0.6/1.2/1.8 mg, A1C drops of 1.0-1.5%, and the LEADER trial cardiovascular benefit. With generic liraglutide now available in 2026, this drug has a fresh second life.
GLP-1GLP-1 Insurance Coverage 2026: Medicare Bridge, Medicaid by State, Savings Cards, FSA/HSA
How to actually get Wegovy or Zepbound covered in 2026. Commercial copay cards to $25, the new Medicare GLP-1 Bridge at $50/month starting July 2026, Medicaid coverage in 13 states, FSA/HSA rules, prior auth, and how to appeal a denial.
GLP-1GLP-1 at Costco, CVS, Walmart, and Walgreens: A 2026 Pharmacy Pricing Map
Where to physically fill a Wegovy, Ozempic, or Zepbound prescription in 2026 — cash prices, member programs, retail clinic visits, and manufacturer-direct pickup compared across the major chains.
GLP-1Hims GLP-1 Review: The $49 Pill Era Ended in March 2026 — What's Left
Hims settled with Novo Nordisk on March 9, 2026 and exited compounded semaglutide for new patients. Pricing is now $249-$399/month for branded drugs plus a $149 membership. Worth it?
GLP-1GLP-1 and Pregnancy: Washout Timing, Breastfeeding, and Unintended Exposure (2026)
Semaglutide and tirzepatide are contraindicated in pregnancy. Here is the exact washout period before conception, what to do if pregnancy happens unexpectedly, what current data show about birth defects, and how breastfeeding guidance differs between injection and oral forms.
GLP-1GLP-1 and GIP: How Two Gut Hormones Drive the Most Effective Weight-Loss Drugs
GLP-1 gets the headlines, but it is the addition of GIP that makes tirzepatide outperform semaglutide. The mechanism is surprising — and tirzepatide actually binds GLP-1 weaker than the hormone it mimics.
GLP-1GLP-1 Before and After: Month-by-Month Weight Loss Timeline (Real Data)
Trials show 15–22% mean weight loss over 18 months on a GLP-1. Real-world data is much lower — about 2% at 72 weeks on older drugs at standard doses. Here is the full curve and what drives the gap.
GLP-1GLP-1 Reviews 2026: What Real Patients Rate Zepbound, Wegovy, Ozempic, and Mounjaro
Aggregated patient reviews across Drugs.com and WebMD: Zepbound 8.7/10, Mounjaro 8.4/10, Wegovy 7.4/10, Ozempic 6.7/10. What people love, what they hate, and why fewer than 1 in 4 stay on past a year.
GLP-1GLP-1 Supplements: Drops, Gummies, and Boosters — What's In Them, What They Cost, What They Do
Injectable semaglutide raises GLP-1 by over 1,000%. The best OTC supplement gummies raise it by ~17%. Here's the brand-by-brand breakdown — ingredients, prices, evidence, and what they're really worth.
GLP-1GLP-1 Benefits for Women: PCOS, Menopause, Fertility, and What's Different in 2026
Women lose more total weight than men on GLP-1s on average but progress slightly slower per dose. The drugs normalize cycles in ~80% of PCOS responders, drive an Ozempic baby boom in once-infertile women, and reduce breast cancer risk signals — while raising bone density and hair loss concerns unique to female biology.
GLP-1GLP-1 and Kidney Disease: FLOW Trial Data and Ozempic's FDA-Approved CKD Indication
FDA approved Ozempic (semaglutide) on January 28, 2025 to slow kidney disease progression in adults with type 2 diabetes and CKD. The FLOW trial in 3,533 patients showed a 24% reduction in major kidney events — independent of weight loss.
GLP-1How to Boost GLP-1 Naturally: Foods, Exercise, and Habits That Actually Work
Your body makes GLP-1 every time you eat — but DPP-4 destroys it within 1-2 minutes. Protein, soluble fiber, healthy fats, fermented foods, and exercise amplify the pulse. Here's the evidence-based playbook.
GLP-1GLP-1 for Heart Failure: STEP-HFpEF, SUMMIT, and Why HFpEF Is Where the Data Lives
Semaglutide and tirzepatide both improve symptoms in obesity-related HFpEF. STEP-HFpEF: +7.8 KCCQ points, -13.3% weight. SUMMIT: 38% lower risk of CV death or worsening heart failure with tirzepatide.
GLP-1GLP-1 Face (Ozempic Face): Mechanism, Prevention, and What Actually Treats It
Dermatologist Dr. Paul Jarrod Frank coined the term in 2022. Beyond rapid weight loss, new research shows GLP-1 receptors directly affect adipose stem cells, fibroblasts, and collagen synthesis — explaining why the face ages faster than the rest of the body.
GLP-1GLP-1 Recipes: 15 High-Protein Meals That Won't Trigger Nausea (2026)
Fifteen specific GLP-1-friendly recipes with exact ingredients, protein grams, calorie counts, and gentle cooking methods. Plus a sample 100g protein day and a list of dishes to avoid because of GI side effects.
GLP-1GLP-1 Lawsuits 2026: Where MDL-3094 and MDL-3163 Stand Today
More than 3,600 federal lawsuits allege gastroparesis, NAION blindness, and other injuries from GLP-1 drugs. Bellwether trials are expected mid-2026. Here is the full status.
GLP-1GLP-1 Online: The 9 Telehealth Providers Worth Knowing in 2026
The compounded free-for-all is over. After the FDA cleared the shortage list and sent 55+ warning letters, GLP-1 telehealth split into branded-only and compounded-503A camps. Here is each major provider's real pricing, medication list, and trade-offs.
GLP-1GLP-1 vs GLP-2: Same Gene, Two Completely Different Drug Classes
GLP-1 and GLP-2 come from the same proglucagon gene and are released by the same intestinal cells — but they hit different receptors, do different jobs, and treat completely different diseases. One is the basis of Ozempic. The other is the basis of a $300,000-a-year drug for short bowel syndrome.